Precigen Inc. (PGEN) Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for PRGN-2012
- Wall Street ends higher, notches weekly gains as Fed meeting looms
- Intel pares losses but sheds $9 billion in value on dire outlook, dividend concerns
- Analysts rush to cut Intel (INTC) price targets following weaker than expected Q1 guidance
- Lucid Group (LCID) doubles on Saudi rumors
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ immunotherapy in patients with recurrent respiratory papillomatosis (RRP).
The company will host an R&D Day virtual event today at 4:30 PM ET to showcase the data and will feature presentations by Clint T. Allen, MD, Senior Investigator, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute (NCI) and lead associate investigator for the PRGN-2012 clinical trial, and Precigen's President and CEO, Helen Sabzevari, PhD. Participants may register and access the live webcast through Precigen's investor relations website in the Events & Presentations section.
"As a patient and an advocate on behalf of the RRP community, the potential for a therapeutic alternative to surgical intervention would be nothing short of life changing," said Kim McClellan, President, Recurrent Respiratory Papillomatosis Foundation (RRPF). "There has never been a therapeutic option for the RRP patient community and we are incredibly hopeful that this will change in the near future. Our community faces ongoing risks from hospitalizations and repeat surgeries, coupled with daily quality-of-life challenges, such as obstructed breathing, difficulties swallowing, and impaired speech, and our community bears a tremendous financial burden from the significant lifetime costs to patients and their families affiliated with this disease."
"RRP is a rare disease with no cure. The current standard-of-care is repeated surgery to treat symptoms, which exposes patients to surgical risks, emotional distress and poses a significant economic burden to families and the healthcare system overall. We are thrilled to present these Phase 1 results today as PRGN-2012 has the potential to improve the lives of patients with severe, aggressive RRP through reduced surgeries," said Helen Sabzevari, PhD, President and CEO of Precigen. "Any treatment that reduces the burden of surgeries in RRP is considered meaningful and in the PRGN-2012 Phase 1 study, 50% of patients had a Complete Response, requiring no surgeries as of the data cutoff with a minimum of 12 months following treatment."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Senesco Technologies, Inc. (SNTI) Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
- Nemaura Medical (NMRD) Prices 4.8M Share Offering at $1.75/sh
- Sol-Gel Technologies Ltd. (SLGL) Announces 2.56M Share Offering at $5/sh
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!